WallStreetSavant.com Announces Profile Coverage of Skystar Bio-Pharmaceutical


BEAVERTON, Ore., Dec. 5, 2006 (PRIME NEWSWIRE) -- Wall Street Savant, LLC (www.wallstreetsavant.com) today announced that it has initiated Profile Coverage on Skystar Bio-Pharmaceutical (OTCBB:SKBI) on its website. Skystar Bio-Pharmaceutical is a China based producer and distributor of vaccines, microorganisms and 100% organic herbal additives to cure and prevent disease in poultry, livestock, birds and pets. The company's product line consists of more than 70 state-of-the-art products with over 50 additional products in the developmental stage. One of the prominent products currently in the development stage is a feed additive and vaccine for Avian Influenza. Skystar has formed strategic sales distribution networks in 27 provinces and regions throughout China. Skystar recently completed construction of new state-of-the-art Bio-Pharmaceutical facilities covering an area of almost eight acres. The new facilities meet or exceed all Good Manufacturing Practice (GMP) Certification Standards and have received GMP Certification from the Chinese government.

To view Skystar Bio-Pharmaceutical's Profile please visit www.wallstreetsavant.com.

About WallStreetSavant.com

WallStreetSavant.com is a leading online financial portal where investors can discover an array of financial tools to help build their investment IQ. WallStreetSavant.com also provides comprehensive profiles on undiscovered and under-followed micro and small-cap companies as well as well researched opinions on stocks for active traders. The comprehensive profiles are featured on WallStreetSavant.com and members are kept abreast on all new developments through regular email updates.

To join our free email list please click here: http://www.wallstreetsavant.com/mailer/user/register.php

To feature your publicly traded company on WallStreetSavant.com, please contact us at 1-800-281-6469 or via email at info@wallstreetsavant.com.

Forward-Looking Statements: With the exception of historical information, this news release and accompanying information may include forward-looking statements that involve a number of risks and uncertainties. Actual results could differ materially from those anticipated as a result of various risks. There are numerous factors that could contribute to such differences; therefore, such projected events and anticipated results are not warranties or guarantees that such events will occur or that the Company will achieve such results. For more information about this corporation and risks involved in the investment of their publicly traded shares, please see the Company's web site, and/or documents filed with the SEC. Disclosure: Wall Street Savant LLC was compensated twenty five thousand shares of Skystar's Rule 144 stock restricted for twelve-months by the Company for profile coverage. Wall Street Savant LLC is not a registered investment advisers or broker/dealer. Wall Street Savant LLC makes no recommendation that the purchase of securities of companies profiled in its web site is suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.


            

Contact Data